Off-label drug use approval declined

The Hicksons Health Law Blog includes a note by Karen Kumar and Cameron Leaver, regarding aninteresting recent decision of the Administrative Appeals Tribunal of Australia. The applicant sought (but was refused) approval to import a growth hormone for intended ‘anti-aging” use.

See Rice and Minister for Health [2015] AATA 312 at [18] where the tribunal concluded:

… there is no objective evidence that the therapy already undertaken has had therapeutic benefit, no research that suggests that the therapy would have therapeutic benefit in the future for Mr Rice and the consensus view of highly qualified medical specialists is against the use of hormone growth therapy in Mr Rice’s circumstances.